Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Conclusions: The reported ADRs were consistent with the known safety profile of empagliflozin.Trial registration: ClinicalTrials.gov identifier: NCT02489942.
PMID: 31769309 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Japan Health | Jardiance | SGLT2 Inhibitors | Sodium | Study | Urinary Tract Infections